The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Theraputics Inc (ACRS) | COM | 00461U105 | 1,199 | 634,455 | SH | SOLE | 634,455 | 0 | 0 | ||
| Aeglea Biotherapeutics Inc (AGLE) | COM | 00773J103 | 9,864 | 1,291,151 | SH | SOLE | 1,291,151 | 0 | 0 | ||
| Arcus Biosciences, Inc. (RCUS) | COM | 03969F109 | 3,367 | 333,333 | SH | SOLE | 333,333 | 0 | 0 | ||
| Atreca (BCEL) | CL A COM | 04965G109 | 5,997 | 387,653 | SH | SOLE | 387,653 | 0 | 0 | ||
| AVROBIO, Inc. (AVRO) | COM | 05455M100 | 17,978 | 893,079 | SH | SOLE | 893,079 | 0 | 0 | ||
| BridgeBio (BBIO) | COM | 10806X102 | 134,442 | 3,835,722 | SH | SOLE | 3,835,722 | 0 | 0 | ||
| Eidos Therapeutics, Inc. (EIDIX) | COM | 28249H104 | 64,485 | 1,123,630 | SH | SOLE | 1,123,630 | 0 | 0 | ||
| Marker Therapeutics, Inc. (MRKR) | COM | 57055L107 | 5,760 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
| Nabriva Therapeutics plc (NBRV) | SHS | G63637105 | 2,522 | 1,910,287 | SH | SOLE | 1,910,287 | 0 | 0 | ||
| ObsEva SA (OBSV) | COM | H5861P103 | 5,296 | 1,386,338 | SH | SOLE | 1,386,338 | 0 | 0 | ||
| Sunesis Pharmaceuticals, Inc. (SNSS) | COM | 867328700 | 3,411 | 10,100,000 | SH | SOLE | 10,100,000 | 0 | 0 | ||
| Verona Pharma plc (VRNA) | COM | 925050106 | 2,551 | 443,596 | SH | SOLE | 443,596 | 0 | 0 | ||
| Zosano Pharma Corporation (ZSAN) | COM | 98979H202 | 4,132 | 2,718,226 | SH | SOLE | 2,718,226 | 0 | 0 | ||